Biocon Share Price in Focus; Secures Market Entry for Yesintek in Additional Global Markets

Biocon has secured market entry rights for Yesintek, its proposed biosimilar to Stelara, across nine additional markets under a licensing agreement with Janssen Sciences Ireland, as per the exchange filing. 

The agreement covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, with the rights effective immediately. 

Nine Markets Added to Existing Licensing Arrangements 

The latest agreement builds on earlier arrangements that established market entry dates for Yesintek in the United States, Europe, the United Kingdom, Canada and Japan. 

Yesintek is a biosimilar to ustekinumab, a medicine used in immune-mediated conditions. Biocon's statement lists Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis among its approved treatment indications. 

Stelara Recorded $6.08 Billion in 2025 Sales 

The reference product, Stelara, recorded worldwide sales of $6.08 billion in 2025, according to figures reported by Johnson & Johnson. 

Biocon said the additional market access would allow it to offer an affordable and effective treatment option for patients affected by autoimmune diseases in the newly covered markets. 

Read More: Ramco Systems Share Price in Focus Post Q2 FY27 Earnings Results: Total Income Up 3.5% YoY! 

Biocon Share Price Performance  

As of 26 October 2026, at 11:08 AM, Biocon Ltd share price is trading at ₹325 per share, reflecting a surge of 0.46% from the previous trading session. 

Conclusion 

The agreement with Janssen Sciences Ireland expands Yesintek's market access to nine additional countries and regions, building on Biocon's earlier licensing arrangements. The move extends the proposed biosimilar's reach across more international markets, with Stelara having recorded $6.08 billion in worldwide sales in 2025. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.